Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets
| Autor: | Catherine S. Rangel, Monika Matzner, Guillermo Gonzales, James A. Rybski, Catherine M. Spier, Thomas P. Miller, Thomas M. Grogan, Catherine P. Leith |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty T-Lymphocytes Immunophenotyping Predictive Value of Tests medicine Humans Intermediate Grade Survival analysis B cell Aged B-Lymphocytes L-Lactate Dehydrogenase business.industry Lymphoma Non-Hodgkin Nuclear Proteins Middle Aged medicine.disease Prognosis Small cleaved cells Survival Analysis Lymphocyte Subsets Lymphoma medicine.anatomical_structure Ki-67 Antigen Oncology Predictive value of tests Immunohistochemistry Female business Cell Division |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(8) |
| ISSN: | 0732-183X |
| Popis: | PURPOSE AND METHODS Diffuse small cleaved-cell lymphoma (DSCL) is a relatively uncommon non-hodgkin's lymphoma (NHL) in the United States and has not been the subject of recent in-depth study of factors predictive of outcome. It is unique among the NHL of intermediate grade because there is no evidence of a curable subset of patients. To investigate whether any laboratory data might predict outcome, we studied 33 cases collected during a 12-year period and correlated morphology, immunohistochemistry, and serum lactate dehydrogenase (LDH) with clinical data and outcome. RESULTS We found that proliferative rate (Ki-67), cell lineage (T v B cell), and serum LDH were associated with significant differences in survival. A Ki-67 value greater than or equal to 20% was associated with a median survival of 20 months compared with 80 months for lower values (P = .0002); patients with tumors of T-cell lineage had a median survival of 20 months compared with 40 months for those with B-cell neoplasms (P = .0143); and a serum LDH greater than 225 IU/L was associated with a median survival of 8 months compared with 40 months for lower LDH levels (P = .0004). Blastoid morphology was also linked to a trend toward poor outcome (P = .08). Neither a history of low-grade lymphoma nor the presence of residual immunologically detectable follicles influenced outcome (P = .93 and .97, respectively). CONCLUSION We conclude that high Ki-67, high LDH, and T-cell lineage each identify DSCL patients with poor outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|